Explore how partial reprogramming using Yamanaka factors reverses epigenetic aging, with recent advances in mice and early clinical trials paving the way for rejuvenation therapies. Partial reprogramm...
New research reveals that pulsed electromagnetic fields can activate gene therapy in aged mice, improving survival and reducing aging markers, but ethical questions loom. A groundbreaking study demons...
The 2025 longevity investment landscape shifts from narrow anti-aging to a full innovation stack, led by cellular reprogramming, brain longevity diagnostics, and platform infrastructure. Investors pou...
Life Biosciences launches a Phase I trial for cellular reprogramming to treat age-related macular degeneration, challenging aging norms with FDA’s Plausible Mechanism Pathway, amid rising invest...
The FDA’s updated guidelines on cellular reprogramming, highlighted by Life Biosciences’ ER-100 trial for eye conditions, signal a pivotal shift that could accelerate anti-aging therapies,...
Recent advancements in cellular reprogramming, including significant funding and clinical trials, are transforming anti-aging science by targeting root causes of age-related diseases. Cellular reprogr...
Recent advances in partial cellular reprogramming using OSKM factors show promise in extending healthspan and treating age-related diseases, with biotech firms accelerating towards human trials. New r...
Recent studies show that targeting engrams with partial reprogramming factors improves memory in mouse models, offering a potential therapy for Alzheimer’s and age-related cognitive decline. New...
Life Biosciences receives FDA clearance for the first human trial of cellular reprogramming targeting glaucoma and NAION, signaling regulatory openness to longevity therapies and potential vision rest...
Recent studies show small molecules efficiently mimic Yamanaka factors to reverse epigenetic aging, with clinical trials on the horizon, offering a safer alternative to gene therapies. Advancements in...